REVIC
VC Fund
Tokyo, Japan
REVIC is an organization that supports the business revitalization of small and medium-sized enterprises and regional revitalization in order to revitalize Japan's regional economy and contribute to strengthening the foundation of credit order. It was established in March of the year by reorganizing its predecessor, the Enterprise TurnaroundInitiative Corporation. It supports the business feasibility evaluation conducted by regional financial institutions to provide solutions that match the life stages of local companies, based on the current situation and issues of the regional economy and industry.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 28%
- Fund size:
- $4.8M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries REVIC invests in
Stages REVIC invests in
Countries REVIC invests in
Round sizes
Round size
- Seed
- $15k–$8.1M
- Series C
- $4.2M–$27M
- Venture - Series Unknown
- $388k–$6.3M
Investment Focus
Industry
- Health Care 7 (18%)
- Manufacturing 7 (18%)
- Medical 6 (15%)
- Software 4 (10%)
- Nursing and Residential Care 4 (10%)
Stage
- Venture - Series Unknown 15 (38%)
- Seed 8 (21%)
- Series C 4 (10%)
- Series A 3 (8%)
- Series B 3 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PROVIGATE is a provider of bio-transistor sensor technologies in Japan.The company's technologies are able to measure dynamic changes with the help of perception-broadening sensors, enabling individuals to change their habits for health | $5.4M / Venture - Series Unknown / Oct 28, 2024 | ||
| Exportation of Japanese agricultural products is currently small in volume. While Japanese farmers aspire to export their products to foreign countries for more people to enjoy and local consumers universally share the positive perception of the quality of Japanese agricultural products, issues such as price, communication, and logistics hinder theexpansion of exportation.They aim to solve these issues and satisfy the needs of both Japanese farmers and global consumers which are so clearly evident but devastatingly unmet. | $26.8M / Series C / May 30, 2024 | ||
| Koala Tech Inc. is an innovative high-tech startup company, whose goal is to pioneer practical applications of the world's first organic semiconductor laser diode that has been realized in the Center for Organic Photonics and Electronics Research (OPERA) at Kyushu University. | $2.4M / Series B / Dec 19, 2023 | ||
| Farm Notebook is an IT venture for the development of Farmnote, a specialized herd management system for the dairy and livestock industries. To the vision, through the development of IT systems that can take advantage of the information in the easy as handwritten notes to help the appropriate management decision-making by aggregating all dataranch. It will promote the management efficiency of the dairy and livestock industries in IT with state-of-the-art technology. | $7.2M / Series B / Aug 09, 2023 | ||
| KOTOBUKI Medical is a new business. The company manufactures high-fidelity synthetic organs and surgical training systems out of konjac, a gelatinous plant fiber. | $728.3K / Series A / May 28, 2021 | ||
| Epsilon Molecular Engineering is a Biotechnology research and development company. | $2.7M / Series A / Dec 23, 2020 | ||
| MT3 is a developer of radiosensitizer technology designed to offer treatment to animals suffering from tumors. They provide therapeutic agents, treat forms of tumors, and offer anti tumor treatment. | Seed / Nov 19, 2020 | ||
| Amanek is a real estate company that specializes in hotel development, investment, and management. | $4.9M / Venture - Series Unknown / Dec 10, 2019 | ||
| KOTOBUKI Medical is a new business. The company manufactures high-fidelity synthetic organs and surgical training systems out of konjac, a gelatinous plant fiber. | $277.8K / Seed / Oct 31, 2019 | ||
| PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.The company leverages technology to develop rapidly changing cell therapies and mesenchymal stem cells therapies, enabling clients to fight a variety of diseases and change the future of transplantation medicine. | $82.2M / Series A / Jun 19, 2019 | ||
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does REVIC invest in?
REVIC invests primarily in Health Care, Manufacturing and Medical startups, most often at Venture - Series Unknown and Seed stage. Most of the 39 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is REVIC's check size?
REVIC typically joins rounds of $15k–$8.1M at Seed, $4.2M–$27M at Series C and $388k–$6.3M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds REVIC participates in.
When did REVIC last invest?
The most recent investment recorded for REVIC closed in Oct 2024. Shizune tracks 39 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
